Pain Genetics: How Your Genes Determine Your Pain Sensitivity

Have you ever noticed that some people seem to feel pain far more intensely than others — even when exposed to the exact same stimulus? That difference is not psychological weakness or exaggeration: it has a deep biological basis, written in the DNA. Pain perception is one of the most complex processes in the human body, involving peripheral receptors in the skin and muscles, spinal cord relay stations, and central nervous system circuits that modulate, amplify, or dampen pain signals. A significant portion of this complexity is genetically determined.

In recent years, the genomics of pain has emerged as a fascinating field, revealing variants in genes such as SCN9A, COMT, OPRM1, and TRPV1 that explain why some people are hypersensitive to pain, why certain individuals respond poorly to common analgesics, and why chronic pain conditions carry a strong hereditary component. Understanding your pain genetics is a decisive step toward treating, preventing, and managing pain in a truly personalized way.

What Is Pain Perception and Why Does It Vary So Much?

Pain is not simply the direct result of tissue damage: it is an experience constructed by the nervous system based on multiple factors — the intensity of the stimulus, emotional state, attention, context, and, fundamentally, individual genetic constitution. The process begins at nociceptors, specialized nerve endings that detect potentially harmful stimuli (heat, pressure, inflammatory chemicals). The signal is then transmitted to the brain via specific nerve fibers, where it is processed, modulated, and integrated with other information to produce the conscious experience of pain.

This multi-stage process involves dozens of proteins — ion channels, receptors, enzymes, and neurotransmitters — whose genes carry functional variants in the population. The result is an enormous diversity in pain sensitivity: people with certain variants in SCN9A may be insensitive to pain from birth; others, with variants in COMT or OPRM1, may exhibit central amplification of pain signals and a higher risk of chronic pain.

The Core Genes of Pain Perception

SCN9A — The Sodium Channel and the Extremes of Sensitivity

The SCN9A gene (chromosome 2q24) encodes the alpha subunit of the voltage-gated sodium channel Nav1.7, expressed predominantly in dorsal root ganglion neurons — the nerve cells that transmit pain signals from the periphery to the spinal cord. This channel is absolutely central to the generation and propagation of action potentials in nociceptive neurons.

What makes SCN9A unique is the breadth of phenotypes caused by its variants. Gain-of-function mutations — which render the channel hyperactive — cause conditions such as inherited erythromelalgia, characterized by episodes of intense burning pain in the extremities, and paroxysmal extreme pain disorder. Conversely, loss-of-function mutations result in congenital insensitivity to pain (CIP), a rare condition in which the individual never feels pain — which sounds desirable but is highly dangerous, since pain is a vital warning signal.

At the population level, common polymorphisms in SCN9A — such as rs6746030 (A/G) — are associated with variations in pain sensitivity in healthy individuals. A study by Reimann et al. published in the Proceedings of the National Academy of Sciences (2010) showed that carriers of the A allele had significantly lower pain thresholds and greater sensitivity in experimental pain tests, compared with carriers of the G allele.

COMT — The Enzyme That Regulates Pain in the Brain

The COMT gene (Catechol-O-Methyltransferase, chromosome 22q11) encodes an enzyme responsible for degrading catecholamines — dopamine, adrenaline, and noradrenaline — in the brain and peripheral nervous system. These neurotransmitters play a central role in pain modulation: dopamine and noradrenaline activate opioid and adrenergic receptors that inhibit pain transmission, while epinephrine can, paradoxically, sensitize nociceptors in contexts of stress.

The most-studied polymorphism is Val158Met (rs4680), a valine-to-methionine substitution at position 158 of the protein. The Met158 variant reduces COMT enzyme activity by 3 to 4 times, leading to accumulation of catecholamines at synapses. Although this might seem beneficial (more dopamine = more pleasure), the net effect in the context of pain is negative: the excess catecholamines sensitize peripheral nociceptors through beta-adrenergic receptor activation and reduce the efficiency of descending pain-inhibition systems.

Homozygous Met/Met carriers show greater sensitivity to experimental pain, higher risk of developing chronic temporomandibular joint disorder (Diatchenko et al., Nature Genetics, 2005), and greater vulnerability to fibromyalgia and other chronic pain syndromes. This variant also influences the response to opioid analgesics: Met/Met carriers tend to require higher doses of morphine to achieve the same pain relief as Val/Val carriers.

"The COMT val158met polymorphism is among the most functionally important and best-studied variants in pain genetics, with demonstrable effects on both experimental and clinical pain outcomes across multiple populations."

— Diatchenko et al., Nature Genetics, 2005

OPRM1 — The Opioid Receptor and Analgesic Response

The OPRM1 gene (Opioid Receptor Mu 1, chromosome 6q25) encodes the mu opioid receptor, the principal target of endogenous opioids (endorphins, enkephalins) and pharmacological opioid analgesics (morphine, codeine, fentanyl). This receptor mediates the analgesic, euphoric, and dependence-producing effects of opioids, and its activity plays a central role in the physiological regulation of pain.

The A118G polymorphism (rs1799971) substitutes asparagine for aspartate at position 40 of the protein, altering a glycosylation site and reducing receptor expression by approximately 2 to 3 times in carriers of the G allele (118G variant). The consequences are profound: G allele carriers show:

• Lower endogenous opioid system activity, resulting in lower pain thresholds in experimental tests;
• Reduced analgesic response to pharmacological opioids — clinical studies show that G/G carriers require significantly higher doses of post-operative morphine;
• Lower risk of opioid dependence in some studies, suggesting that the reduced euphoria associated with the diminished receptor may be protective;
• Higher risk of chronic pain in conditions such as low back pain and persistent post-surgical pain.

A study by Chou et al. published in Anesthesiology (2006) showed that patients homozygous for 118G/G required 93% more morphine in the first 24 hours after abdominal surgery, compared with A/A carriers — a clinically enormous difference that illustrates the potential of pain pharmacogenomics.

TRPV1 — The Heat and Capsaicin Sensor

The TRPV1 gene (Transient Receptor Potential Vanilloid 1, chromosome 17p13) encodes an ion channel expressed in nociceptors that responds to intense heat (above 43°C), acidic pH, and capsaicin (the active compound in chili peppers). It is the primary thermal pain sensor in the body and plays an important role in neurogenic inflammation and peripheral sensitization in chronic pain conditions.

Polymorphisms such as rs8065080 (I585V) alter the channel's sensitivity to thermal and chemical agonists. Carriers of higher-activity TRPV1 variants show:

• Greater sensitivity to painful heat;
• Greater pain intensity in response to inflammatory stimuli (such as arthritis and bursitis);
• Higher risk of visceral hypersensitivity (such as irritable bowel syndrome with a pain component).

Paradoxically, TRPV1 is also the target of topical treatments based on high-concentration capsaicin: repeated intense stimulation of the channel leads to desensitization and relief of neuropathic pain — an effect exploited in FDA-approved creams and patches for post-herpetic neuralgia.

Key Genes of Pain Sensitivity

Practical Implications: What Your Pain Genetics Mean in Daily Life

Understanding your genetic pain profile has practical implications across several dimensions of health and well-being:

1. Post-Operative and Pharmacological Pain Management

Patients carrying variants in OPRM1 (118G) and COMT (Met158) may need differentiated analgesic protocols after surgery or in acute pain conditions. Informing your physician about your genetic profile can guide the choice between different classes of analgesics and the appropriate doses — reducing both undertreatment of pain and the risk of adverse effects from overdose.

2. Prevention and Treatment of Chronic Pain

People with genetic profiles indicating greater pain sensitivity — especially Met/Met carriers in COMT and those with gain-of-function variants in SCN9A — have a higher risk of progression from acute to chronic pain following injuries or surgeries. Early interventions, such as adequate physiotherapy, stress management (which raises catecholamines and can amplify pain in COMT Met/Met carriers), and mindfulness techniques, can reduce this risk.

3. Exercise Strategy Selection

People with greater genetic pain sensitivity may need more gradual increases in training intensity, greater attention to warm-up and cool-down (particularly relevant for carriers of high-activity TRPV1 variants), and more careful recovery protocols to prevent delayed onset muscle soreness from becoming a limiting factor in exercise adherence.

4. Personalized Anti-Inflammatory Nutrition

Nociceptor sensitization via TRPV1 is amplified in contexts of systemic inflammation. For carriers of higher-activity TRPV1 variants, a diet rich in anti-inflammatory compounds — omega-3 fatty acids, curcumin, polyphenols — may be especially beneficial in reducing the inflammatory amplification of pain.

What helixXY Can Reveal

The helixXY genetic report analyzes functional variants in the key pain sensitivity genes, including SCN9A, COMT, OPRM1, and TRPV1, providing an individualized profile that answers questions such as:

• Do you have a genetic predisposition to greater pain sensitivity?
• Is your endogenous opioid system more or less efficient than average?
• Do you have a higher genetic risk of developing chronic pain conditions?
• How does your genetic profile influence your response to common analgesics?
• Which pain management strategies are most appropriate for your DNA?

Based on this information, helixXY delivers personalized lifestyle, nutrition, and recovery strategy recommendations — always grounded in up-to-date scientific evidence and with guidance for consulting a specialized healthcare provider when necessary.

Important: helixXY reports are informational and educational. Please consult a healthcare professional for medical advice.

References

• Reimann, F. et al. (2010). "Pain perception is altered by a nucleotide polymorphism in SCN9A." Proceedings of the National Academy of Sciences, 107(11), 5148–5153.
• Diatchenko, L. et al. (2005). "Genetic basis for individual variations in pain perception and the development of a chronic pain condition." Nature Genetics, 37(2), 232–234.
• Chou, W. Y. et al. (2006). "Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty." Anesthesiology, 105(5), 904–911.
• Mogil, J. S. (2012). "Pain genetics: past, present and future." Trends in Genetics, 28(6), 258–266.
• Nielsen, C. S. et al. (2012). "Heritability of Nociception: A Population-Based Twin Study." Pain, 153(11), 2233–2239.